



## **The WPA International Congress “Treatment in Psychiatry: A New Update” (Florence, April 1-4, 2009)**

The WPA International Congress “Treatments in Psychiatry: A New Update” will take place in Florence, Italy, from 1 to 4 April, 2009. It will be the follow-up to the 2004 WPA International Congress “Treatments in Psychiatry: An Update”, which was the second most attended psychiatric congress worldwide in that year, with almost 7,000 partici-

pants. This time, more than 8,000 participants are expected.

The Congress aims to provide a high-quality, comprehensive overview of all evidence-based treatments currently available for all mental disorders. Many of the most renowned experts in the various treatment areas will be among the speakers.



The Congress will consist of the following components: a) ESI<sup>SM</sup> Top-Cited Scientist Lectures (delivered by the scientists who attracted the highest total citations to their papers in indexed journals of psychiatry and psychology over the past 10 years, according to the Essential Science Indicators); b) Update Lectures (providing a comprehensive update on some of the most significant aspects of current treatments in psychiatry); c) Update Symposia (focusing on specific treatment issues, with an active interaction between speakers and participants); d) Advanced Courses (in which a well-known expert will interact with no more than 50 participants); e) Regular Symposia (high-quality Symposia selected from those submitted by April 30, 2008); f) Workshops (high-quality sessions dealing with very specific treatment issues, selected from those submitted by April 30, 2008); g) Section and Zonal Symposia or Workshops (organized by WPA Scientific Sections or Zones); h) New Research Sessions; i) Poster Sessions.

Please find below the list of the ESI<sup>SM</sup> Top-Cited Scientist Lectures, Update Lectures, Update Symposia and Advanced Courses. The final programme of the Congress is available on the website [www.wpa2009florence.org](http://www.wpa2009florence.org).

### ESI<sup>SM</sup> Top-Cited Scientist Lectures

TL1. *R.C. Kessler* – The treatment gap in psychiatry

TL2. *K.S. Kendler* – Psychiatric genetics: a current perspective

TL3. *H.S. Akiskal* – Bipolarity: a broad spectrum (spectra) in search of treatment

TL4. *S. McElroy* – Pharmacotherapy of binge eating disorder

TL5. *M. Rutter* – Environmental causes of mental disorder

TL6. *R.M. Murray* – The causes of schizophrenia: the striatum and the street

TL7. *M.E. Thase* – Long-term management of depression: the role of pharmacotherapy and psychotherapies

TL8. *P.E. Keck* – What is a mood stabilizer?

TL9. *D.J. Kupfer* – Medical burden in

bipolar disorder

TL10. *A.J. Rush* – Getting the evidence for evidence based care of depression: how to narrow the knowledge gap

### Update Lectures

UL1. *R.J. Baldessarini* – Disorders, syndromes, target symptoms: how do we choose medications?

UL2. *P. Fonagy* – Psychotherapies: what works for whom?

UL3. *K.W.M. Fulford* – Values-based practice and psychiatric diagnosis: bringing values and evidence together in policy, training and research

UL4. *S.G. Resnick* – Recovery and positive psychology: empiricism or attitude?

UL5. *G. Thornicroft* – Steps, challenges and mistakes to avoid in the development of community mental health care: a framework from experience

UL6. *P.D. McGorry* – Early intervention in psychiatry

UL7. *M.F. Green* – Improving cognitive performance and real-world functioning in people with schizophrenia

UL8. *E. Vieta* – Evidence-based comprehensive management of bipolar disorder

UL9. *R.E. Drake* – Management of patients with co-occurring substance abuse and severe mental disorder

UL10. *M. Stone* – Comprehensive management of borderline personality disorder in ordinary clinical practice

UL11. *W.W. Fleischhacker* – Comparative efficacy, effectiveness and cost-effectiveness of antipsychotics in the treatment of schizophrenia

UL12. *P.J. Weiden* – The art and science of switching antipsychotic medications

UL13. *G.A. Fava* – Combined and sequential treatment strategies in depression and anxiety disorders

UL14. *K.A. Halimi* – Multimodal management of anorexia and bulimia nervosa

### Update Symposia

US1. The evolving science and practice of psychosocial rehabilitation (*Chairperson: R. Warner*)

*son: R. Warner*)

US2. Anxiety disorders: from dimensions to targeted treatments (*Chairperson: J. Zohar*)

US3. Treatment advances in child psychiatry (*Chairperson: J.L. Rapoport*)

US4. Outcome in bipolar disorders: new findings and methodological findings (*Chairperson: M. Tohen*)

US5. Management of medically unexplained somatic symptoms (*Chairperson: O. Gureje*)

US6. The future of psychotherapies for psychoses (*Chairperson: P. Bebbington*)

US7. Advances in the management of treatment-resistant depression (*Chairperson: S. Kasper*)

US8. ICD-11 and DSM-V: work in progress (*Chairperson: M. Maj*)

US9. Gender-related issues in psychiatric treatments (*Chairperson: D. Stewart*)

US10. Suicide prevention: integration of public health and clinical actions (*Chairperson: Z. Rihmer*)

US11. Brain imaging in psychiatry: recent progress and clinical implications (*Chairperson: L. Farde*)

US12. Advances in the management of treatment-resistant bipolar disorder (*Chairperson: G.B. Cassano*)

US13. Partnerships in mental health care (*Chairperson: B. Saraceno*)

US14. Genomics and proteomics in psychiatry: an update (*Chairperson: N. Craddock*)

US15. Patterns of collaboration between primary care and mental health services (*Chairperson: V. Patel*)

US16. Effectiveness and cost-effectiveness of pharmacological treatments in psychiatry: evidence from pragmatic trials (*Chairperson: J. Lieberman*)

US17. Cognitive impairment: should it be part of the diagnostic criteria for schizophrenia? (*Chairperson: R. Keefe*)

US18. Cultural issues in mental health care (*Chairperson: P. Ruiz*)

US19. Advances in the management of treatment-resistant psychotic disorders (*Chairperson: H.-J. Möller*)

US20. Violence, trauma and victimization (*Chairperson: A. McFarlane*)

US21. The challenge of bipolar depression (*Chairperson: J. Calabrese*)



US22. Novel biological targets of pharmacological treatment in mental disorders (*Chairperson: G. Racagni*)

US23. Intermediate phenotypes in psychiatry (*Chairperson: D. Weinberger*)

US24. Current management of mental disorders in old age (*Chairperson: C. Katona*)

US25. Prevention and early intervention strategies in community mental health settings (*Chairperson: S. Saxena*)

US26. Managing comorbidity of mental and physical illness (*Chairperson: N. Sartorius*)

US27. Mental health care in low-resource countries (*Chairperson: P. Deva*)

US28. Prevention of substance abuse worldwide (*Chairperson: M.E. Medina-Mora*)

#### Advanced Courses

AC1. Interacting with families of people with severe mental disorders (*Director: C. Barrowclough*)

AC2. Management of the suicidal patient (*Director: D. Wasserman*)

AC3. The therapeutic alliance in psychiatric practice (*Directors: A. Tasman, J. Kay*)

AC4. Management of mental disorders during pregnancy and post-partum (*Director: I. Brockington*)

AC5. How to organize a comprehensive community mental health service (*Directors: G. Thornicroft, M. Tansella*)

AC6. Prevention and management of burnout in mental health professionals (*Director: W. Rössler*)

AC7. Measures of outcome in schizo-

phrenia (*Director: R. Kahn*)

AC8. Assessing and training neurocognitive functions in patients with chronic psychoses (*Director: S. Galderisi*)

AC9. Consultation-liaison psychiatry: learning from experience (*Director: F. Creed*)

AC10. Relevance of phenomenological psychiatry to clinical practice (*Director: G. Stanghellini*)

AC11. The psychiatrist in court (*Director: J. Arboleda-Florez*)

AC12. Management of the "difficult" child (*Director: S. Tyano*)

AC13. The public health approach: what psychiatrists need to know (*Directors: H. Herrman, S. Saxena*)

AC14. Interpersonal psychotherapy of depression (*Director: T. Gruetter*)

## CALL FOR PROPOSALS OF RESEARCH PROJECTS TO BE SUPPORTED BY THE WPA AND CONDUCTED BY ITS SCIENTIFIC SECTIONS

The World Psychiatric Association (WPA) is the largest association active in the mental health field worldwide, with 134 Member Societies (national psychiatric societies), in 122 countries, representing more than 200,000 psychiatrists.

The scientific backbone of the Association is represented by its 65 Scientific Sections, covering practically every aspect of psychiatry. According to the WPA statutes, one of the purposes of these Sections is the promotion and conduction of international collaborative research, a purpose which has been only partially achieved up to now, mainly due to financial constraints.

The WPA is going to fund two high-quality research projects proposed by its Scientific Sections. The projects will have to deal with one of the following issues highlighted in the WPA Action Plan 2008-2011: 1. Depression in persons with physical diseases. 2. Stigmatization of psychiatry and psychiatrists. 3. Integration of mental health care into primary care. 4. Protection and promotion of physical health in persons with severe mental disorders. 5. Assessment and development of talents and strengths of persons with mental disorders.

Proposals from individual Sections or networks of Sections are welcome. They will have to include a description of the project (max. 3000 words, including an introduction, the objectives, the methodology and some references), a list of the participating centres, a timetable, and a detailed budget. A short curriculum vitae of the proposed principal investigator(s) is also requested (no more than one page). Proposals will have to be sent by e-mail to the WPA Secretariat ([wpasecretariat@wpanet.org](mailto:wpasecretariat@wpanet.org)) by June 30, 2009.

